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ABSTRACT 
Background: Coronary artery disease (CAD), worldwide, is the most common type of heart 
disease. Adherence to the evidence-based medications for secondary prevention is associated with 
further improvement in the outcomes.  
Objectives: To identify level of adherence towards secondary prevention medications among 
Sudanese ischemic heart disease patients. 
Materials and Methods: This is a cross sectional hospital-based study, performed in the period 
from August 2012 through January 2013.Audit of Adherence of Sudanese Cardiac Patients to 
Secondary Prevention of Ischemic Heart Disease at Elshaab Teaching Hospital Khartoum, Sudan 
was done using a questionnaire for assessment.  
Results: A total of 210 patients were included in this study. Their mean (±SD) age was 60.8(±12.3) 
years. Of them, 190 patients have high risk factors and 167 were on regular follow up. 
195(92.9%)patients were on ACEI/ARBs and Aspirin. 116(55.2%) were on clopidogrel and 203 
(96.7%) on statin. 
Conclusion: 140(66.7%) patients were strictly adherent to medications, 21(10%) partially adherent 
and 49(23.3%) were totally not adherent. Lack of adherence was mainly due to poverty and high 
cost of medications. 
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oronary heart disease (CHD) is the 
leading cause of death in the USA 
and other developed countries1. 
Recently there is an increasing 
attention to the evidence-based treatment 
after myocardial infarction2,3. A lot of studies 
and recommended guidelines have shown 
that discharge treatment of aspirin, 
clopidogrel, beta-blockers, Angiotensin 
Converting Enzyme Inhibitors (ACEI) or 
Angiotensin Receptor Blockers (ARBs), 
Aldosterone antagonist and cholesterol-
lowering therapy after a Myocardial 
Infarction (MI) are associated with   
improved   outcomes4-7.   Adherence to 
evidence-based secondary prevention 
medications    is   associated    with     further  
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improvement   in   outcomes and   maximally 
reduces the burden of CHD8-10. Previous 
studies has demonstrated that adherence to 
post-MI medications, is poor11,8,12. 
Adherence is a priority for better-quality 
measures and quality-improvement 
interventions. Barriers to beta-blocker 
adherence for low-income populations need 
particular attention13. However, follow-up 
after myocardial infarction for long time is 
very limited in most studies, therefore 
difficult to assess adherence for more than 
one year post myocardial infarction. In 
addition, many of the studies have been 
conducted with limited clinical information 
about the population. Hence, there is limited 
research on factors associated with long-term 
adherence for recommended secondary 
prevention medications. 
This study aimed at identifying level of 
adherence towards secondary prevention 
medications among Sudanese ischemic heart 
disease patients. 
C 
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MATERIALS AND METHODS: 
Study design:  
Crosssectional hospital based study. 
Study area: Elshaab Teaching Hospital 
(STH) is a tertiary care hospital, in Khartoum 
state, Sudan. There are six cardiac outpatient 
clinics per week in this hospital.  
Study Population: 
Patients attending Cardiac Referred Clinic at 
Elshaab Teaching Hospital diagnosed as 
cases of Ischemic Heart Disease (IHD) or 
Acute Coronary Syndrome (ACS). 
Study period: From August 2012 through 
January 2013.   
Inclusion criteria: 
All patients diagnosed and treated in hospital 
as ACS [ST Segment Elevation Myocardial 
Infarction (STEMI) or Non-ST Segment 
Elevation Myocardial Infarction (NSTEMI), 
Unstable Angina] or Ischemic Heart Disease 
(IHD).  
Exclusion criteria: 
1. Patients who lost contact with the 
hospital. 
2. Failure to give consent. 
3. Patients who recently started taking 
secondary prevention medications in less 
than one month.  
Tools of the study: 
Pretested questionnaire and direct interviews 
were done. The questionnaire gathered data 
on patient’s age, sex, body weight, level of 
education, smoking habits, type of  
jobs, causes of stress, evidence of 
hyperlipidaemia, diabetes, hypertension, 
longevity of the disease, number of hospital 
admissions, life style, period of adherence to 
the medications in the study namely Aspirin, 
clopidogrel, Statins, β-Blockers, ACE 
Inhibitors or (ARBs) and Aldactone . 
The questionnaire was pretested with 30 
patients to reach a common consensus of 
understanding to each and every question. 
The pretested questionnaire was filled by 
investigator. The “Don’t know” option was 
included to minimize guessing of the 
response. Most of the patients were Arabic 
speaking natives; therefore the questionnaire 
was translated into Arabic language. One 
questionnaire was allotted for each patient 
regardless of his/her number of visits to the 
clinic during the study period.  
Data analysis: 
Data were fed to Statistical Package of Social 
Sciences (SPSS) version 18. Means and 
standard deviations were computed where 
appropriate. One sample t test and 
correlations were obtained and statistical 
significant difference was taken at P = 0.05. 
Ethical clearance: 
This study was approved by the Quality and 
Training Administration at Elshaab Teaching 
Hospital. All patients were included after 
reading and signing the informed consent 
attached to questionnaire.  
A pilot questionnaire was administered to 30 
patients who were diagnosed as ACS or IHD 
in order to evaluate their understanding of 
the questions. This helped in designing the 
final version. A total 210 patients were 
included in this study.  Patients were selected 
according to the final diagnosis. Medications 
taken for control of the disease were 
obtained.  
RESULTS: 
The patients were 103(49%) male and 
107(51%) female. Their mean (±SD) age was 
60.8 (±12.3) years (Table 1). 




   Male 103(49%) 
   Female 107 (51%) 
Age (Mean ± SD)  60.8 (±12.3)yrs 
Educational Level  
    Illiterate 61(29 %) 
    Preschool  31(14.8%) 
    Basic School 61(29%) 
    Secondary School 39(18.6%) 
    University 14(6.7%) 
    Postgraduate 4(1.9%) 
 
Similar family history obtained from 
74(35.2%) patients. Nine (4.3%) patients 
were smokers at the time of the study, and 
67(31.9%) patients were ex-smokers. Also, 
23 (11%) snuffers and 17 (8.1%) are ex-
snuffers. The distribution of frequencies of 
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standard thresholds9. However, our rates od 
adherence were better than what was reported 
in another study14. 
The commonest cause of poor adherence to 
treatment of secondary prevention, in our 
study, was poverty and poverty plus other 
causes (patient were either not convinced 
about the importance of the medications, not 
well educated about adherence benefits, 
feeling well, annoyed with side effects, and/or 
became intolerant to continue on 
medications). Our findings were consistent 
with other studies regarding adherence to 
statin and other secondary prevention 
medications22-25.Nevertheless, a study report 
in Sao Paulo, Brazil concluded that adherence 
of patients to use of medications was far from 
satisfactory, mainly due to the high cost of the 
medications26. 
In this study, we found statistically significant 
result in the relation between way of 
obtaining medications and adherence (χ2 = 
8.280   P = 0.013). Our results showed that 
the commonest way to obtain medications 
was the health insurance. In spite of the help 
of the Health Insurance Fund, few insured 
patients were poorly adherent or completely 
in-adherent to their medications. Their poor 
adherence was probably explained by other 
factors such as being not convinced to 
importance of medications, not well educated 
about benefits of adherence, feeling well, 
annoyed with side effects, and/or intolerance 
to continue on medications. This is in keeping 
with findings of other published studies which 
added more reasons for intentional non-
adherence as believing the medications were 
not needed and perceiving ineffectiveness of 
therapy, annoyed with the complexity of the 
regimen, and suffer of inability to afford the 
medication27-28. Also, others had reported 
that, treatment side-effects, cognitive 
impairment, poor healthcare provider-patient 
relationships, and difficulties accessing 
physicians or pharmacies have all been 
identified as relevant factors were adding to 
the problem of poor adherence25. 
In this study we found that, there was 
significant statistical difference in relation 
between the follow up period and regularity 
of intake of medications. Patients who were 
regular in their follow up were adherent to 
their medications (χ2 = 37.373 P = 0.0001). 
This is consistent with the literature14. 
In this study there were 84(40%) housewives, 
56 of them were fully adherent, eight partially 
adherent and 20 were not adherent at all. In 
contrast, another study showed statistical 
significance, in women and nursing home 
residents been adherent to beta-blockers and 
ACEI/ARBs but not statins15. 
Also, we found that the level of academic 
education did not affect the adherence of 
patients to their drugs (χ2 = 8.183   P = 
0.3790) but probably the severity of the 
disease, phobia from its bad consequences 
and the doctors-patient health education play 
a good role in keeping the majority of patients 
adherent to their drugs. One of the factors of 
non-adherence is the inadequate 
communication between healthcare workers 
and patients, resulting in the patient’s failure 
of following medical recommendations. This 
was stated as evident fact in older and semi-
illiterate patients29. 
We have small number of smoker patients in 
our study but, there was no significant 
statistical difference in patients who were 
smokers, not smokers or ex-smokers and their 
adherence (χ2 = 3.552   P = 0.1450). This 
finding is similar to the fact mentioned in 
another study that smoking at the time of 
myocardial infarction appeared to be 
associated with an increased likelihood of 
discontinuing cardio-protective medications14. 
Also, in our data we found that there was 
significant statistical difference in adherence 
of patients who had three or less admissions 
compared to the poor adherence of those who 
had frequent admissions (χ2 = 36.663 P= 
0.0340). However, there was no significant 
statistical difference in adherence of patients 
who were admitted for seven days or more (χ2 
= 27.461 P= 0.9460). This is similar to 
another study that reported patients who were 
in the hospital for more than a week were 
more likely to discontinue therapy compared 
to those with shorter stays13. 
On the other hand, we found that there was 
significant statistical difference in adherence 
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of patients who had early and late diagnosis 
(χ2 = 76.0520 P= 0.5720). This is consistent 
with the study that reported rates of adherence 
among old users of drugs to be significantly 
higher than those among patients were newly 
prescribed medications following their MI. 
However, the trends in adherence for recent 
and previously diagnosed patients did not 
differ for ACEI/ARB, beta-blockers, or all the 
three study medications. In contrast, patients 
newly prescribed statins after their MI had 
greater improvements over time than for old 
statin users (P<0.0010)15. 
CONCLUSION: 
Males and females in Sudan patients were 
affected equally by IHD/ACS with a peak 
frequency at 45-65 years of age. There was no 
significant statistical difference in their 
adherence regarding the differences in sex 
and age. We encountered few smokers and 
ex-smokers that did not show significant 
statistical differences regarding their 
adherence. 
Poverty seems to adversely affect adherence. 
This occurs in spite of the support of the 
Health Insurance Fund, because some 
subgroups of medication are not covered by 
the umbrella of the insurance programme. 
However, this needs to be tackled carefully 
and ethically by the policy-makers and health 
providers within the health economic policies. 
On the other hand, the level of academic 
education and the patients' jobs seems to have 
no impact on adherence to secondary 
prevention of IHD/ACS medications.The 
longer the duration of admission adversely 
affects adherence, but the frequency of 
readmissions doesn't affect adherence. 
Further researches are advised to be done in 
this area with a larger sample size and longer 
term follow up, to validate the results of this 
study. 
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